Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

It didn’t take long to find exceptions to your “not more than double” postulate.

Ocera-Mallinckrodt “Ocera started the day with a market cap at $26 million, making this a bite-sized buyout for the likes of Mallinckrodt. They’re paying $42 million for the stock — at $1.52 each along with $75 million in contingent value rights for the company.” That’s 4 times the cap.

Allergan-Tobira “This lowered its market cap to below $100 million but at the end of play yesterday, this had dropped by nearly half, to just $52 million.” “Allergan ($AGN) has snapped up tiny Tobira ($TBRA) and its struggling fatty liver disease candidate, along with the rest of its pipeline, for potentially $1.7 billion.” let’s see, even taking the 100 million number, that’s 17 times the cap.

By the way, both of those were for drugs that failed trials. So let’s also see, how many trials has IPIX failed?

I would go find a couple of examples of drug startups that have been purchased for like 30 to 50 times their caps, but I’m either too busy or too lazy to do that. I leave that to someone else. Meanwhile, I’ll leave it at, partnerships and acquisitions are barely connected to caps and share price, even if barely connected.